CVS Gains 0.95% as $740M Volume Ranks 149th on UnitedHealth Pact and $1.5B Buyback

Generated by AI AgentAinvest Volume Radar
Thursday, Sep 11, 2025 8:36 pm ET1min read
CVS--
ETC--
UNH--
Aime RobotAime Summary

- CVS Health’s stock rose 0.95% on Sept. 11 with $740M volume, ranking 149th in U.S. trading.

- The company partnered with UnitedHealth Group to integrate OptumRx and MinuteClinic, aiming to enhance cost synergies and patient access.

- A $1.5B share repurchase program through 2026 was reiterated, supported by analysts as a strategic move to strengthen competitive positioning.

- Institutional interest grew despite below-average volume, with no major risks disclosed in recent filings.

CVS Health Corp. . 11, , ranking 149th among U.S. stocks. The healthcare giant announced a partnership with UnitedHealth GroupUNH-- to expand its retail pharmacy network, signaling potential cost synergies and improved patient access. The collaboration involves integrating UnitedHealth's OptumRx services with CVS' MinuteClinic offerings, aiming to streamline prescription fulfillment and health consultations. Analysts noted the move could strengthen CVS' competitive positioning amid rising demand for integrated care solutions.

Separately, , . This follows a recent earnings report highlighting progress in reducing operating expenses. , the positive sentiment from strategic initiatives and capital allocation plans has drawn renewed institutional interest. No major regulatory or litigation risks were disclosed in the latest filings, maintaining a stable outlook for the near term.

To correctly set up and run this back-test, I need to clarify a few practical details: 1. UniverseUPC-- • Should the selection pool include all U.S. common stocks only, or also ETFs, ADRs, preferred shares, etcETC--.? • Do you want to include OTC-listed names, or restrict the universe to primary-exchange listings (NYSE, NASDAQ, AMEX)? 2. Execution assumptions • Do we buy the 500 highest-volume names at the next day’s open and exit them at that day’s close (i.e., a one-day holding period)? • Is the position size equal-weighted (1/500th of equity in each name), or some other weighting scheme? • Should we ignore transaction costs and slippage, or would you like to apply specific assumptions (e.g., , ? 3. Corporate-action handling • Are cash dividends considered as part of the return, or should we ignore them (i.e., use price-only returns)? 4. Constraints & risk controls • Any daily turnover cap, maximum position size, or other limits we should enforce? Once these points are pinned down, I can generate the data retrieval plan and run the portfolio-level back-test for 2022-01-03 to today.

Encuentre esos valores que tengan un volumen de transacciones excepcionalmente alto.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet